These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 2470358)
1. Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease. Müller B; Krais T; Stürzebecher S; Witt W; Schillinger E; Baldus B Biomed Biochim Acta; 1988; 47(10-11):S40-4. PubMed ID: 2470358 [TBL] [Abstract][Full Text] [Related]
2. Iloprost in peripheral vascular disease--platelet function and clinical outcome. Fitscha P; Tiso B; Sinzinger H Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993 [No Abstract] [Full Text] [Related]
3. Clinical benefits of iloprost, a stable prostacyclin (PGI2) analog, in severe peripheral arterial disease (PAD). Oberender H; Krais T; Schäfer M; Belcher G Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():311-6. PubMed ID: 2473610 [No Abstract] [Full Text] [Related]
4. Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD). Fitscha P; Tiso B; Krais T; Sinzinger H Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():450-4. PubMed ID: 2444079 [No Abstract] [Full Text] [Related]
5. [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study]. Diehm C; Abri O; Baitsch G; Bechara G; Beck K; Breddin HK; Brock FE; Clevert HD; Corovic D; Marshall M Dtsch Med Wochenschr; 1989 May; 114(20):783-8. PubMed ID: 2470569 [TBL] [Abstract][Full Text] [Related]
6. The influence of iloprost on blood rheology and tissue perfusion in patients with intermittent claudication. Ciuffetti G; Sokola E; Lombardini R; Pasqualini L; Pirro M; Mannarino E Kardiol Pol; 2003 Sep; 59(9):197-204. PubMed ID: 14618196 [TBL] [Abstract][Full Text] [Related]
7. Does prostacyclin analogue Iloprost change blood rheology? Results from a double blind trial with intravenous application in diabetics. Ernst E; Marshall M; Matrai A Vasa; 1988; 17(2):89-91. PubMed ID: 2457284 [No Abstract] [Full Text] [Related]
8. Clinical benefit and prolongation of platelet half-life induced by CG 4203, a stable PGI2-analogue. Kaliman J; Fitscha P; Barth H; Sinzinger H Prog Clin Biol Res; 1987; 242():469-77. PubMed ID: 3313421 [No Abstract] [Full Text] [Related]
9. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion. Thiemermann C; Schrör K Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783 [TBL] [Abstract][Full Text] [Related]
10. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group. Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148 [TBL] [Abstract][Full Text] [Related]
12. Possibilities for clinical use of prostacyclin in vascular disease. Poredos P Pflugers Arch; 2000; 440(5 Suppl):R137-8. PubMed ID: 11005643 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic effectiveness of prostaglandins (PGs) in peripheral vascular disease (PVD). Linet OI; Mohberg NR Adv Prostaglandin Thromboxane Leukot Res; 1989; 19():307-10. PubMed ID: 2473609 [No Abstract] [Full Text] [Related]
14. Vascular prostacyclin release and metabolic derangement in diabetes. Harrison HE; Johnson M Horm Metab Res Suppl; 1981; 11():43-9. PubMed ID: 7033096 [TBL] [Abstract][Full Text] [Related]
15. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Cronenwett JL; Zelenock GB; Whitehouse WM; Lindenauer SM; Graham LM; Stanley JC Surgery; 1986 Aug; 100(2):369-75. PubMed ID: 3526609 [TBL] [Abstract][Full Text] [Related]
16. Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease. Sinzinger H; Virgolini I; O'Grady J Prog Clin Biol Res; 1989; 301():85-96. PubMed ID: 2477859 [No Abstract] [Full Text] [Related]
17. [Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative]. Brock FE; Abri O; Baitsch G; Bechara G; Beck K; Corovic D; Diehm C; Marshall M; Rahmel B; Scheffler P Schweiz Med Wochenschr; 1990 Oct; 120(40):1477-82. PubMed ID: 1699272 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, crossover comparison of iloprost with dextran in patients with peripheral arterial occlusive disease. Ylitalo P; Kaukinen S; Reinikainen P; Salenius JP; Vapaatalo H Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):197-204. PubMed ID: 1694831 [TBL] [Abstract][Full Text] [Related]
19. In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins. Fitscha P; Kaliman J; O'Grady J; Sinzinger H Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):443-6. PubMed ID: 2465949 [TBL] [Abstract][Full Text] [Related]
20. Platelet responses observed during and after infusions of the prostacyclin analog ZK 36 374. Yardumian DA; Mackie IJ; Bull H; Machin SJ Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():359-62. PubMed ID: 2408446 [No Abstract] [Full Text] [Related] [Next] [New Search]